AHN Highlights
- Total Animal Health sales: $1.615B (+9%, +7% ex-FX)
- Livestock sales: $1.023B (+16%, +14% ex-FX)
- Companion Animal sales: $592M (–2%, –3% ex-FX)
- BRAVECTO: $262M (–1% YoY; –3% ex-FX)
- Drivers: Livestock demand; parasiticide competition and fewer vet visits in companion animal
Merck & Co. reported Animal Health sales of $1.615 billion for Q3 2025, up 9% year over year (+7% ex-FX). The company cited strong livestock performance as the primary driver of growth, while companion animal revenue was modestly lower.
Livestock: Sales rose to $1.023 billion (+16%, +14% ex-FX), reflecting higher demand across species and some timing effects.
Companion Animal: Revenue was $592 million (–2%, –3% ex-FX), with Merck noting reduced veterinary visits and competitive pressure in parasiticides, partly offset by higher pricing, improved supply, and new product launches.
BRAVECTO: Sales were $262 million vs. $266 million a year ago (–1%, –3% ex-FX).
Information from company press release.
